Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00064077 · ClinicalTrials.gov registry record · Phase 3
Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix
A Phase 3 study, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 513
- Enrollment target
NCT00064077 is a Phase 3 study that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 513 participants.
The verdict
NCT00064077, a Phase 3 study, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 513 participants
- Enrollment target
Study Summary
This randomized phase III trial is studying four combination chemotherapy regimens using cisplatin to compare how well they work in treating women with stage IVB, recurrent, or persistent cancer of the cervix. Drugs used in chemotherapy such as cisplatin, paclitaxel, vinorelbine, gemcitabine, and topotecan, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen containing cisplatin is most effective in treating cervical cancer.
Interventions
- DRUG Cisplatin
- OTHER Quality-of-Life Assessment
- DRUG Paclitaxel
- DRUG Gemcitabine Hydrochloride
- DRUG Topotecan Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 513 participants |
| Start Date | 2003-05 |
| Est. Completion | 2018-01-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00064077
The ClinicalTrials.gov registry entry for NCT00064077 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 513 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT00064077 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00064077 about?
NCT00064077 is a clinical study titled "Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix". This randomized phase III trial is studying four combination chemotherapy regimens using cisplatin to compare how well they work in treating women with stage IVB, recurrent, or persistent cancer of the cervix. Drugs used in chemotherapy such as cisplatin, paclitaxel, vinorelbine, gemcitabine, and to...
What is the current status of trial NCT00064077?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 513 participants. The study started on 2003-05. Estimated completion is 2018-01-30.
What interventions are being tested in trial NCT00064077?
The interventions under investigation include: Cisplatin (DRUG), Quality-of-Life Assessment (OTHER), Paclitaxel (DRUG), Gemcitabine Hydrochloride (DRUG), Topotecan Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00064077?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.